+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Plasma Protein Therapeutics Market by Product, Indication, Route of Administration, Dosage Form, Treatment Pattern, Plasma Source Type, Line of Therapy, Therapy Combination, Age Group, End User - Global Forecast 2026-2032- Product Image
Plasma Protein Therapeutics Market by Product, Indication, Route of Administration, Dosage Form, Treatment Pattern, Plasma Source Type, Line of Therapy, Therapy Combination, Age Group, End User - Global Forecast 2026-2032- Product Image
Sale

Plasma Protein Therapeutics Market by Product, Indication, Route of Administration, Dosage Form, Treatment Pattern, Plasma Source Type, Line of Therapy, Therapy Combination, Age Group, End User - Global Forecast 2026-2032

  • Report

  • 195 Pages
  • June 2026
  • Region: Global
  • 360iResearch™
  • ID: 4968904
UP TO OFF until Jan 01st 2027
1h Free Analyst Time
Description Jump to:
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.
The Plasma Protein Therapeutics Market is projected to reach USD 31.97 Billion in 2026. It is expected to continue growing at a CAGR of 5.35%, reaching USD 43.78 Billion by 2032.

Plasma protein therapeutics are essential biologic medicines manufactured from human plasma or by recombinant technologies to replace, modulate, or supplement critical proteins. The category includes immunoglobulins, albumin, coagulation factors, alpha-1 proteinase inhibitor, C1 esterase inhibitor, and other specialty plasma-derived therapies used across primary immunodeficiency, chronic inflammatory demyelinating polyneuropathy, immune thrombocytopenia, hemophilia, hereditary angioedema, liver disease, shock, burns, and critical care.

The market is shaped by a distinctive operating model: supply begins with qualified plasma donors, continues through highly regulated plasma collection and fractionation, and ends with life-sustaining therapies subject to stringent quality, viral safety, pharmacovigilance, and cold-chain standards. Demand is structurally resilient because many indications require recurring or lifelong treatment, while supply expansion depends on donor center capacity, regulatory approvals, fractionation yield, and national plasma collection policies.

For SEO and market positioning, the most important industry themes are rising immunoglobulin utilization, persistent plasma collection constraints, broader use of recombinant and long-acting therapies, regional self-sufficiency strategies, and digitalization of plasma operations. These factors are redefining competitive advantage for manufacturers, contract fractionators, specialty distributors, health systems, and investors in plasma protein therapeutics.

Transformative Shifts in the Plasma Protein Therapeutics Landscape

The plasma protein therapeutics landscape is undergoing a shift from volume-led expansion to resilience-led growth. Manufacturers are investing in donor recruitment, collection-center productivity, fractionation capacity, and yield optimization as immunoglobulin demand continues to outpace many other plasma-derived product categories. Regulatory expectations from agencies such as the U.S. FDA and the European Medicines Agency reinforce the need for validated manufacturing processes, donor traceability, pathogen reduction, and robust quality systems.

Clinical practice is also transforming. Subcutaneous immunoglobulin is increasingly used for eligible patients who need more flexible administration, while recombinant coagulation factors and non-factor therapies have changed treatment pathways in hemophilia. At the same time, albumin remains deeply linked to hospital care, liver disease management, and intensive care protocols, making demand sensitive to clinical guidelines, hospital formularies, and reimbursement policies.

The competitive landscape is consolidating around organizations that can integrate plasma collection, fractionation, clinical evidence generation, regulatory compliance, and specialty distribution. Supply security, geographic diversification, patient-centric delivery formats, and validated quality systems are now as important as product portfolios in determining long-term leadership.

Cumulative Impact of Artificial Intelligence

Artificial intelligence is creating cumulative value across the plasma protein therapeutics value chain by improving decisions in donor operations, manufacturing, clinical development, and post-market surveillance. AI-enabled analytics can support donor appointment scheduling, donor retention modeling, inventory planning, and demand forecasting, helping organizations reduce supply volatility in a category where collection capacity directly influences therapy availability.

In manufacturing, machine learning can strengthen process monitoring, deviation detection, batch-release analytics, and predictive maintenance for fractionation facilities. These applications align with broader regulatory interest in data integrity, quality-by-design, computerized system validation, and continuous process verification, provided models are validated and governed under appropriate quality management systems.

AI also has relevance in clinical and safety functions. Natural language processing can accelerate pharmacovigilance signal detection, while real-world evidence analytics can help clarify treatment patterns, adherence, dosing variability, and outcomes for immunoglobulin, albumin, coagulation factors, and rare disease therapies. The cumulative impact is not replacement of established biologics expertise, but faster and more reliable execution across highly regulated workflows.

Key Regional Insights

North America remains a pivotal region for plasma protein therapeutics because the United States is the world’s largest source of collected plasma and a major demand center for immunoglobulin, albumin, and coagulation therapies. The region benefits from mature reimbursement systems, extensive specialty pharmacy networks, advanced diagnosis of immune and bleeding disorders, and established FDA oversight for biologics manufacturing and plasma collection. Canada adds a highly regulated healthcare environment with strong clinical demand and national attention to secure access for plasma-derived medicinal products.

Europe is characterized by strong regulatory harmonization through the European Medicines Agency and national competent authorities, although plasma collection and self-sufficiency policies vary by country. The European Union’s focus on supply security, safety standards, pharmacovigilance, and cross-border medicinal product regulation continues to influence investment in fractionation capacity and plasma-derived medicinal product access. The United Kingdom, Germany, France, Italy, and Spain remain important treatment environments for immunology, hematology, neurology, and critical care indications.

Asia-Pacific is one of the most important development regions as China, India, Japan, South Korea, and Australia expand diagnosis, hospital infrastructure, biologics access, and regulatory capabilities. Japan, South Korea, and Australia show mature quality oversight and established specialty care, while China and India are shaped by large patient populations, evolving reimbursement, and domestic plasma policy. Latin America, led by Brazil and Mexico, shows rising demand but remains affected by uneven reimbursement, import dependence, and access disparities. The Middle East, particularly government-funded systems in the Gulf, is focused on imported therapy access and health security, while Africa faces the greatest challenges from limited domestic fractionation capacity, constrained diagnostics, and cold-chain reliability. Across all regions, donor policy modernization, public health investment, and dependable logistics are decisive for plasma protein therapeutics access.

Key Group Insights

The G7 countries anchor global demand for plasma protein therapeutics because they combine high healthcare expenditure, established diagnostic pathways, mature pharmacovigilance systems, and broad access to specialty biologics. Within this group, the United States, Japan, Germany, France, the United Kingdom, Italy, and Canada influence clinical standards, reimbursement decisions, quality expectations, and treatment adoption across immunoglobulin therapy, albumin use, hemophilia care, and rare disease management.

The European Union is central to regulatory alignment, pharmacovigilance, plasma-derived medicinal product policy, and cross-border supply security, while NATO countries collectively represent a large group of high-income healthcare systems where emergency preparedness, resilient medical supply chains, and biologics availability are increasingly relevant. BRICS markets are gaining strategic importance as China, India, and Brazil expand biologics access and hospital infrastructure, while Russia and South Africa reflect more variable access dynamics due to local policy, funding, and procurement conditions.

ASEAN presents long-term development potential as Indonesia, Thailand, Vietnam, Malaysia, the Philippines, and Singapore improve specialty care, diagnostic capability, and hospital infrastructure. GCC markets, including Saudi Arabia, the United Arab Emirates, Qatar, Kuwait, Bahrain, and Oman, are shaped by government-funded healthcare, import reliance, national health security priorities, and growing interest in specialized biologics access. Together, these blocs reveal a plasma protein therapeutics environment increasingly defined by regional procurement strategy, regulatory convergence, supply resilience, and plasma self-sufficiency ambitions.

Key Country Insights

The United States is the most influential country in plasma protein therapeutics because of its large plasma collection network, FDA-regulated biologics framework, advanced specialty pharmacy distribution, and high utilization of immunoglobulin therapies. Canada participates through strong clinical demand, regulated access, and health-system focus on stable supply. Mexico and Brazil represent important Latin American markets where diagnosis, reimbursement coverage, public procurement, and import dependence influence adoption of immunoglobulin, albumin, coagulation factors, and other plasma-derived therapies.

In Europe, Germany, France, Italy, Spain, and the United Kingdom have established treatment pathways for primary immunodeficiency, neurology, hematology, critical care, and rare disease indications. Germany and France are notable for sophisticated hospital systems and structured reimbursement pathways, while Italy and Spain combine broad public healthcare access with tendering and regional purchasing dynamics. The United Kingdom’s clinical access is shaped by national guidance, specialized commissioning, and post-Brexit regulatory considerations. Russia remains a distinct market due to localization priorities, procurement controls, and variable access conditions. Across these countries, national health technology assessment, tendering, pharmacovigilance, and hospital purchasing policies shape therapy availability.

China and India are high-potential countries supported by large patient populations, expanding healthcare capacity, and increasing attention to rare disease and immunology diagnosis, while access continues to depend on reimbursement evolution, domestic plasma policy, and supply reliability. Japan shows mature biologics access, rigorous regulatory oversight, and established care for immunology, neurology, and hematology indications. South Korea combines advanced hospital infrastructure with strong regulatory capacity and increasing specialty biologics use. Australia has a highly regulated blood and plasma policy environment, strong clinical governance, and stable demand for plasma-derived and recombinant alternatives. Country-level performance depends on diagnosis rates, donor systems, reimbursement coverage, domestic manufacturing or import access, and the ability to secure continuity of treatment.

Actionable Recommendations for Industry Leaders

Industry leaders should prioritize supply resilience by expanding ethical plasma collection, improving donor retention, diversifying sourcing geographies, and investing in fractionation yield. Because plasma-derived therapies are vulnerable to collection disruptions, integrated planning across collection, manufacturing, quality, regulatory affairs, and distribution is essential.

Organizations should also strengthen evidence generation. Real-world data, patient registries, health economic analyses, and outcomes research can support payer discussions, refine dosing practices, and demonstrate value in immunoglobulin, albumin, coagulation therapies, and rare disease indications. Collaboration with clinicians, patient organizations, blood establishments, and regulators can improve diagnosis, appropriate utilization, and treatment continuity.

Digital transformation should be deployed selectively and responsibly. AI-enabled forecasting, quality analytics, donor engagement, inventory planning, and pharmacovigilance can deliver measurable value when supported by validated data, cybersecurity controls, auditability, and regulatory-grade governance. Leaders that combine supply security, clinical credibility, manufacturing excellence, and operational intelligence will be best positioned for sustainable growth.

Research Methodology

This executive summary is developed using a structured secondary-research approach focused on verifiable public sources, regulatory references, clinical guidelines, and industry evidence. Key inputs include information from the U.S. FDA, European Medicines Agency, World Health Organization, national health agencies, peer-reviewed immunology and hematology literature, clinical practice guidance, and established plasma industry resources.

The methodology emphasizes triangulation across demand drivers, product categories, regional policy environments, manufacturing constraints, healthcare access indicators, regulatory requirements, and documented therapeutic uses. Insights are assessed for consistency with established biologics frameworks, plasma collection and fractionation standards, pharmacovigilance expectations, and observed industry dynamics in cold-chain distribution and specialty medicine access.

Qualitative interpretation is applied to identify strategic implications for manufacturers, investors, distributors, healthcare providers, and public health stakeholders. No unsupported market-size estimate, market share statement, or forecast is used where a verifiable figure is not provided, preserving reliability and executive decision relevance.

Conclusion

Plasma protein therapeutics remain a critical segment of biologic medicine because they address severe, chronic, rare, and often life-threatening conditions where treatment continuity matters. The category is supported by immunoglobulin demand, specialty indications, improved diagnosis, hospital use of albumin, advances in hemophilia care, and broader access to advanced biologics.

At the same time, development is constrained by plasma availability, complex manufacturing, stringent regulatory requirements, cold-chain demands, and reimbursement pressure. The organizations best positioned for durable performance will be those that improve supply resilience, invest in quality and data systems, generate robust clinical evidence, and adapt to regional self-sufficiency priorities.

Artificial intelligence, recombinant innovation, and more sophisticated regional strategies will accelerate the next phase of plasma protein therapeutics evolution. For industry leaders, the category offers durable clinical relevance, but only disciplined execution can convert medical need into reliable patient access and sustainable competitive advantage.

 

Additional Product Information:

  • Purchase of this report includes 1 year online access with quarterly updates.
  • This report can be updated on request. Please contact our Customer Experience team using the Ask a Question widget on our website.

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Definition
1.3. Market Segmentation & Coverage
1.4. Years Considered for the Study
1.5. Currency Considered for the Study
1.6. Language Considered for the Study
1.7. Key Stakeholders
2. Research Methodology
2.1. Introduction
2.2. Research Design
2.2.1. Primary Research
2.2.2. Secondary Research
2.3. Research Framework
2.3.1. Qualitative Analysis
2.3.2. Quantitative Analysis
2.4. Market Size Estimation
2.4.1. Top-Down Approach
2.4.2. Bottom-Up Approach
2.5. Data Triangulation
2.6. Research Outcomes
2.7. Research Assumptions
2.8. Research Limitations
3. Executive Summary
3.1. Introduction
3.2. CXO Perspective
3.3. Market Size & Growth Trends
3.4. Market Share Analysis, 2025
3.5. FPNV Positioning Matrix, 2025
3.6. New Revenue Opportunities
3.7. Next-Generation Business Models
3.8. Industry Roadmap
4. Market Overview
4.1. Introduction
4.2. Industry Ecosystem & Value Chain Analysis
4.2.1. Supply-Side Analysis
4.2.2. Demand-Side Analysis
4.2.3. Stakeholder Analysis
4.3. Market Dynamics
4.3.1. Key Drivers
4.3.2. Key Restraints
4.3.3. Key Opportunities
4.3.4. Key Challenges
4.4. Porter’s Five Forces Analysis
4.5. PESTLE Analysis
4.6. Market Outlook
4.6.1. Near-Term Market Outlook (0-2 Years)
4.6.2. Medium-Term Market Outlook (3-5 Years)
4.6.3. Long-Term Market Outlook (5-10 Years)
4.7. Go-to-Market Strategy
5. Market Insights
5.1. Consumer Insights & End-User Perspective
5.2. Consumer Experience Benchmarking
5.3. Opportunity Mapping
5.4. Distribution Channel Analysis
5.5. Pricing Trend Analysis
5.6. Regulatory Compliance & Standards Framework
5.7. ESG & Sustainability Analysis
5.8. Disruption & Risk Scenarios
5.9. Return on Investment & Cost-Benefit Analysis
6. Cumulative Impact of Artificial Intelligence 2026
7. Plasma Protein Therapeutics Market, by Product
7.1. Albumin
7.1.1. Five Percent
7.1.2. Twenty Five Percent
7.2. Coagulation Factor
7.2.1. Factor IX
7.2.2. Factor VIII
7.2.3. Prothrombin Complex Concentrate
7.3. Hyperimmune Globulin
7.3.1. Hepatitis B
7.3.2. Rabies
7.3.3. Tetanus
7.3.4. Varicella Zoster
7.4. Immunoglobulin
7.4.1. Intravenous Immunoglobulin
7.4.2. Subcutaneous Immunoglobulin
8. Plasma Protein Therapeutics Market, by Indication
8.1. Cardiovascular
8.2. Neurological
8.3. Primary Immunodeficiency
8.4. Secondary Immunodeficiency
8.5. Trauma
9. Plasma Protein Therapeutics Market, by Route Of Administration
9.1. Intramuscular
9.2. Intravenous
9.3. Oral
9.4. Subcutaneous
10. Plasma Protein Therapeutics Market, by Dosage Form
10.1. Liquid
10.2. Lyophilized Powder
11. Plasma Protein Therapeutics Market, by Treatment Pattern
11.1. Acute
11.2. Episodic
11.3. Chronic
12. Plasma Protein Therapeutics Market, by Plasma Source Type
12.1. Source Plasma
12.2. Recovered Plasma
13. Plasma Protein Therapeutics Market, by Line Of Therapy
13.1. First Line
13.2. Second Line
13.3. Third Line And Beyond
14. Plasma Protein Therapeutics Market, by Therapy Combination
14.1. Monotherapy
14.2. Combination Therapy
15. Plasma Protein Therapeutics Market, by Age Group
15.1. Pediatric
15.2. Adult
15.3. Geriatric
16. Plasma Protein Therapeutics Market, by End User
16.1. Clinics
16.2. Hospitals
17. Asia-Pacific Plasma Protein Therapeutics Market
18. North America Plasma Protein Therapeutics Market
19. Latin America Plasma Protein Therapeutics Market
20. Europe Plasma Protein Therapeutics Market
21. Middle East Plasma Protein Therapeutics Market
22. Africa Plasma Protein Therapeutics Market
23. ASEAN Plasma Protein Therapeutics Market
24. GCC Plasma Protein Therapeutics Market
25. European Union Plasma Protein Therapeutics Market
26. BRICS Plasma Protein Therapeutics Market
27. G7 Plasma Protein Therapeutics Market
28. NATO Plasma Protein Therapeutics Market
29. United States Plasma Protein Therapeutics Market
30. Canada Plasma Protein Therapeutics Market
31. Mexico Plasma Protein Therapeutics Market
32. Brazil Plasma Protein Therapeutics Market
33. United Kingdom Plasma Protein Therapeutics Market
34. Germany Plasma Protein Therapeutics Market
35. France Plasma Protein Therapeutics Market
36. Russia Plasma Protein Therapeutics Market
37. Italy Plasma Protein Therapeutics Market
38. Spain Plasma Protein Therapeutics Market
39. China Plasma Protein Therapeutics Market
40. India Plasma Protein Therapeutics Market
41. Japan Plasma Protein Therapeutics Market
42. Australia Plasma Protein Therapeutics Market
43. South Korea Plasma Protein Therapeutics Market
44. Competitive Landscape
44.1. Market Concentration Analysis, 2025
44.1.1. Concentration Ratio (CR)
44.1.2. Herfindahl Hirschman Index (HHI)
44.2. Recent Developments & Impact Analysis, 2025
44.3. Product Portfolio Analysis, 2025
44.4. Benchmarking Analysis, 2025
45. Company Profiles
45.1. Abeona Therapeutics Inc.
45.2. ADMA Biologics, Inc.
45.3. Amgen Inc.
45.4. Baxter International Inc.
45.5. Bayer AG
45.6. Bharat Serums and Vaccines Limited
45.7. Bio Products Laboratory Limited
45.8. Biogen Inc.
45.9. BioMarin Pharmaceutical Inc.
45.10. Biotest AG
45.11. China Biologic Products Holdings, Inc.
45.12. CSL Limited
45.13. Emergent BioSolutions Inc.
45.14. F. Hoffmann-La Roche Ltd.
45.15. GC Biopharma Corp.
45.16. Grifols S.A.
45.17. Hualan Biological Engineering, Inc.
45.18. Intas Pharmaceuticals Limited
45.19. Kamada Ltd.
45.20. Kedrion S.p.A.
45.21. LFB S.A.
45.22. Novo Nordisk A/S
45.23. Octapharma AG
45.24. Pfizer Inc.
45.25. Prothya Biosolutions B.V.
45.26. Sanofi S.A.
45.27. Sanquin Plasma Products B.V.
45.28. Shanghai RAAS Blood Products Co., Ltd.
45.29. Shenzhen Kangtai Biological Products Co., Ltd.
45.30. Takeda Pharmaceutical Company Limited
List of Figures
FIGURE 1. GLOBAL PLASMA PROTEIN THERAPEUTICS MARKET, YEARS CONSIDERED FOR THE STUDY
FIGURE 2. GLOBAL PLASMA PROTEIN THERAPEUTICS MARKET, RESEARCH DESIGN
FIGURE 3. GLOBAL PLASMA PROTEIN THERAPEUTICS MARKET, RESEARCH FRAMEWORK
FIGURE 4. GLOBAL PLASMA PROTEIN THERAPEUTICS MARKET, DATA TRIANGULATION
FIGURE 5. GLOBAL PLASMA PROTEIN THERAPEUTICS MARKET SIZE, 2018-2032 (USD MILLION)
FIGURE 6. GLOBAL PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY REGION, 2025 VS 2032 (%)
FIGURE 7. GLOBAL PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 8. GLOBAL PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY GROUP, 2025 VS 2032 (%)
FIGURE 9. GLOBAL PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 10. GLOBAL PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY COUNTRY, 2025 VS 2032 (%)
FIGURE 11. GLOBAL PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 12. GLOBAL PLASMA PROTEIN THERAPEUTICS MARKET SHARE, BY KEY PLAYER, 2025
FIGURE 13. GLOBAL PLASMA PROTEIN THERAPEUTICS MARKET, FPNV POSITIONING MATRIX, BY KEY PLAYER, 2025
FIGURE 14. GLOBAL PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY PRODUCT, 2025 VS 2032 (%)
FIGURE 15. GLOBAL PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY PRODUCT, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 16. GLOBAL PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY INDICATION, 2025 VS 2032 (%)
FIGURE 17. GLOBAL PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY INDICATION, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 18. GLOBAL PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025 VS 2032 (%)
FIGURE 19. GLOBAL PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 20. GLOBAL PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY DOSAGE FORM, 2025 VS 2032 (%)
FIGURE 21. GLOBAL PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY DOSAGE FORM, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 22. GLOBAL PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY TREATMENT PATTERN, 2025 VS 2032 (%)
FIGURE 23. GLOBAL PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY TREATMENT PATTERN, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 24. GLOBAL PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY PLASMA SOURCE TYPE, 2025 VS 2032 (%)
FIGURE 25. GLOBAL PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY PLASMA SOURCE TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 26. GLOBAL PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY LINE OF THERAPY, 2025 VS 2032 (%)
FIGURE 27. GLOBAL PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY LINE OF THERAPY, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 28. GLOBAL PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY THERAPY COMBINATION, 2025 VS 2032 (%)
FIGURE 29. GLOBAL PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY THERAPY COMBINATION, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 30. GLOBAL PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY AGE GROUP, 2025 VS 2032 (%)
FIGURE 31. GLOBAL PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY AGE GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 32. GLOBAL PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY END USER, 2025 VS 2032 (%)
FIGURE 33. GLOBAL PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 34. ASIA-PACIFIC PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY REGION, 2025 VS 2032 (%)
FIGURE 35. ASIA-PACIFIC PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 36. NORTH AMERICA PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY REGION, 2025 VS 2032 (%)
FIGURE 37. NORTH AMERICA PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 38. LATIN AMERICA PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY REGION, 2025 VS 2032 (%)
FIGURE 39. LATIN AMERICA PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 40. EUROPE PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY REGION, 2025 VS 2032 (%)
FIGURE 41. EUROPE PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 42. MIDDLE EAST PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY REGION, 2025 VS 2032 (%)
FIGURE 43. MIDDLE EAST PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 44. AFRICA PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY REGION, 2025 VS 2032 (%)
FIGURE 45. AFRICA PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 46. ASEAN PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY GROUP, 2025 VS 2032 (%)
FIGURE 47. ASEAN PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 48. GCC PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY GROUP, 2025 VS 2032 (%)
FIGURE 49. GCC PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 50. EUROPEAN UNION PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY GROUP, 2025 VS 2032 (%)
FIGURE 51. EUROPEAN UNION PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 52. BRICS PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY GROUP, 2025 VS 2032 (%)
FIGURE 53. BRICS PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 54. G7 PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY GROUP, 2025 VS 2032 (%)
FIGURE 55. G7 PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 56. NATO PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY GROUP, 2025 VS 2032 (%)
FIGURE 57. NATO PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 58. UNITED STATES PLASMA PROTEIN THERAPEUTICS MARKET SIZE, 2018-2032 (USD MILLION)
FIGURE 59. CANADA PLASMA PROTEIN THERAPEUTICS MARKET SIZE, 2018-2032 (USD MILLION)
FIGURE 60. MEXICO PLASMA PROTEIN THERAPEUTICS MARKET SIZE, 2018-2032 (USD MILLION)
FIGURE 61. BRAZIL PLASMA PROTEIN THERAPEUTICS MARKET SIZE, 2018-2032 (USD MILLION)
FIGURE 62. UNITED KINGDOM PLASMA PROTEIN THERAPEUTICS MARKET SIZE, 2018-2032 (USD MILLION)
FIGURE 63. GERMANY PLASMA PROTEIN THERAPEUTICS MARKET SIZE, 2018-2032 (USD MILLION)
FIGURE 64. FRANCE PLASMA PROTEIN THERAPEUTICS MARKET SIZE, 2018-2032 (USD MILLION)
FIGURE 65. RUSSIA PLASMA PROTEIN THERAPEUTICS MARKET SIZE, 2018-2032 (USD MILLION)
FIGURE 66. ITALY PLASMA PROTEIN THERAPEUTICS MARKET SIZE, 2018-2032 (USD MILLION)
FIGURE 67. SPAIN PLASMA PROTEIN THERAPEUTICS MARKET SIZE, 2018-2032 (USD MILLION)
FIGURE 68. CHINA PLASMA PROTEIN THERAPEUTICS MARKET SIZE, 2018-2032 (USD MILLION)
FIGURE 69. INDIA PLASMA PROTEIN THERAPEUTICS MARKET SIZE, 2018-2032 (USD MILLION)
FIGURE 70. JAPAN PLASMA PROTEIN THERAPEUTICS MARKET SIZE, 2018-2032 (USD MILLION)
FIGURE 71. AUSTRALIA PLASMA PROTEIN THERAPEUTICS MARKET SIZE, 2018-2032 (USD MILLION)
FIGURE 72. SOUTH KOREA PLASMA PROTEIN THERAPEUTICS MARKET SIZE, 2018-2032 (USD MILLION)
List of Tables
TABLE 1. GLOBAL PLASMA PROTEIN THERAPEUTICS MARKET SEGMENTATION & COVERAGE
TABLE 2. GLOBAL PLASMA PROTEIN THERAPEUTICS MARKET SIZE, 2018-2032 (USD MILLION)
TABLE 3. GLOBAL PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 4. GLOBAL PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 5. GLOBAL PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 6. GLOBAL PLASMA PROTEIN THERAPEUTICS MARKET SHARE, BY KEY PLAYER, 2025
TABLE 7. GLOBAL PLASMA PROTEIN THERAPEUTICS MARKET, FPNV POSITIONING MATRIX, BY KEY PLAYER, 2025
TABLE 8. GLOBAL PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
TABLE 9. GLOBAL ALBUMIN MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 10. GLOBAL ALBUMIN MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 11. GLOBAL ALBUMIN MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 12. GLOBAL FIVE PERCENT MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 13. GLOBAL FIVE PERCENT MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 14. GLOBAL FIVE PERCENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 15. GLOBAL TWENTY FIVE PERCENT MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 16. GLOBAL TWENTY FIVE PERCENT MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 17. GLOBAL TWENTY FIVE PERCENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 18. GLOBAL COAGULATION FACTOR MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 19. GLOBAL COAGULATION FACTOR MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 20. GLOBAL COAGULATION FACTOR MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 21. GLOBAL FACTOR IX MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 22. GLOBAL FACTOR IX MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 23. GLOBAL FACTOR IX MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 24. GLOBAL FACTOR VIII MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 25. GLOBAL FACTOR VIII MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 26. GLOBAL FACTOR VIII MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 27. GLOBAL PROTHROMBIN COMPLEX CONCENTRATE MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 28. GLOBAL PROTHROMBIN COMPLEX CONCENTRATE MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 29. GLOBAL PROTHROMBIN COMPLEX CONCENTRATE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 30. GLOBAL HYPERIMMUNE GLOBULIN MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 31. GLOBAL HYPERIMMUNE GLOBULIN MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 32. GLOBAL HYPERIMMUNE GLOBULIN MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 33. GLOBAL HEPATITIS B MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 34. GLOBAL HEPATITIS B MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 35. GLOBAL HEPATITIS B MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 36. GLOBAL RABIES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 37. GLOBAL RABIES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 38. GLOBAL RABIES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 39. GLOBAL TETANUS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 40. GLOBAL TETANUS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 41. GLOBAL TETANUS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 42. GLOBAL VARICELLA ZOSTER MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 43. GLOBAL VARICELLA ZOSTER MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 44. GLOBAL VARICELLA ZOSTER MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 45. GLOBAL IMMUNOGLOBULIN MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 46. GLOBAL IMMUNOGLOBULIN MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 47. GLOBAL IMMUNOGLOBULIN MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 48. GLOBAL INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 49. GLOBAL INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 50. GLOBAL INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 51. GLOBAL SUBCUTANEOUS IMMUNOGLOBULIN MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 52. GLOBAL SUBCUTANEOUS IMMUNOGLOBULIN MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 53. GLOBAL SUBCUTANEOUS IMMUNOGLOBULIN MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 54. GLOBAL PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
TABLE 55. GLOBAL CARDIOVASCULAR MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 56. GLOBAL CARDIOVASCULAR MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 57. GLOBAL CARDIOVASCULAR MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 58. GLOBAL NEUROLOGICAL MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 59. GLOBAL NEUROLOGICAL MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 60. GLOBAL NEUROLOGICAL MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 61. GLOBAL PRIMARY IMMUNODEFICIENCY MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 62. GLOBAL PRIMARY IMMUNODEFICIENCY MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 63. GLOBAL PRIMARY IMMUNODEFICIENCY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 64. GLOBAL SECONDARY IMMUNODEFICIENCY MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 65. GLOBAL SECONDARY IMMUNODEFICIENCY MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 66. GLOBAL SECONDARY IMMUNODEFICIENCY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 67. GLOBAL TRAUMA MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 68. GLOBAL TRAUMA MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 69. GLOBAL TRAUMA MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 70. GLOBAL PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 71. GLOBAL INTRAMUSCULAR MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 72. GLOBAL INTRAMUSCULAR MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 73. GLOBAL INTRAMUSCULAR MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 74. GLOBAL INTRAVENOUS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 75. GLOBAL INTRAVENOUS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 76. GLOBAL INTRAVENOUS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 77. GLOBAL ORAL MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 78. GLOBAL ORAL MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 79. GLOBAL ORAL MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 80. GLOBAL SUBCUTANEOUS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 81. GLOBAL SUBCUTANEOUS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 82. GLOBAL SUBCUTANEOUS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 83. GLOBAL PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
TABLE 84. GLOBAL LIQUID MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 85. GLOBAL LIQUID MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 86. GLOBAL LIQUID MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 87. GLOBAL LYOPHILIZED POWDER MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 88. GLOBAL LYOPHILIZED POWDER MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 89. GLOBAL LYOPHILIZED POWDER MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 90. GLOBAL PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY TREATMENT PATTERN, 2018-2032 (USD MILLION)
TABLE 91. GLOBAL ACUTE MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 92. GLOBAL ACUTE MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 93. GLOBAL ACUTE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 94. GLOBAL EPISODIC MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 95. GLOBAL EPISODIC MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 96. GLOBAL EPISODIC MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 97. GLOBAL CHRONIC MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 98. GLOBAL CHRONIC MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 99. GLOBAL CHRONIC MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 100. GLOBAL PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY PLASMA SOURCE TYPE, 2018-2032 (USD MILLION)
TABLE 101. GLOBAL SOURCE PLASMA MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 102. GLOBAL SOURCE PLASMA MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 103. GLOBAL SOURCE PLASMA MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 104. GLOBAL RECOVERED PLASMA MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 105. GLOBAL RECOVERED PLASMA MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 106. GLOBAL RECOVERED PLASMA MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 107. GLOBAL PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY LINE OF THERAPY, 2018-2032 (USD MILLION)
TABLE 108. GLOBAL FIRST LINE MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 109. GLOBAL FIRST LINE MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 110. GLOBAL FIRST LINE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 111. GLOBAL SECOND LINE MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 112. GLOBAL SECOND LINE MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 113. GLOBAL SECOND LINE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 114. GLOBAL THIRD LINE AND BEYOND MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 115. GLOBAL THIRD LINE AND BEYOND MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 116. GLOBAL THIRD LINE AND BEYOND MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 117. GLOBAL PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY THERAPY COMBINATION, 2018-2032 (USD MILLION)
TABLE 118. GLOBAL MONOTHERAPY MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 119. GLOBAL MONOTHERAPY MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 120. GLOBAL MONOTHERAPY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 121. GLOBAL COMBINATION THERAPY MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 122. GLOBAL COMBINATION THERAPY MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 123. GLOBAL COMBINATION THERAPY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 124. GLOBAL PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
TABLE 125. GLOBAL PEDIATRIC MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 126. GLOBAL PEDIATRIC MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 127. GLOBAL PEDIATRIC MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 128. GLOBAL ADULT MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 129. GLOBAL ADULT MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 130. GLOBAL ADULT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 131. GLOBAL GERIATRIC MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 132. GLOBAL GERIATRIC MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 133. GLOBAL GERIATRIC MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 134. GLOBAL PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 135. GLOBAL CLINICS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 136. GLOBAL CLINICS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 137. GLOBAL CLINICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 138. GLOBAL HOSPITALS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 139. GLOBAL HOSPITALS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 140. GLOBAL HOSPITALS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 141. ASIA-PACIFIC PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 142. ASIA-PACIFIC PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
TABLE 143. ASIA-PACIFIC PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY ALBUMIN, 2018-2032 (USD MILLION)
TABLE 144. ASIA-PACIFIC PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY COAGULATION FACTOR, 2018-2032 (USD MILLION)
TABLE 145. ASIA-PACIFIC PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY HYPERIMMUNE GLOBULIN, 2018-2032 (USD MILLION)
TABLE 146. ASIA-PACIFIC PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY IMMUNOGLOBULIN, 2018-2032 (USD MILLION)
TABLE 147. ASIA-PACIFIC PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
TABLE 148. ASIA-PACIFIC PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 149. ASIA-PACIFIC PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
TABLE 150. ASIA-PACIFIC PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY TREATMENT PATTERN, 2018-2032 (USD MILLION)
TABLE 151. ASIA-PACIFIC PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY PLASMA SOURCE TYPE, 2018-2032 (USD MILLION)
TABLE 152. ASIA-PACIFIC PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY LINE OF THERAPY, 2018-2032 (USD MILLION)
TABLE 153. ASIA-PACIFIC PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY THERAPY COMBINATION, 2018-2032 (USD MILLION)
TABLE 154. ASIA-PACIFIC PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
TABLE 155. ASIA-PACIFIC PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 156. NORTH AMERICA PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 157. NORTH AMERICA PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
TABLE 158. NORTH AMERICA PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY ALBUMIN, 2018-2032 (USD MILLION)
TABLE 159. NORTH AMERICA PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY COAGULATION FACTOR, 2018-2032 (USD MILLION)
TABLE 160. NORTH AMERICA PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY HYPERIMMUNE GLOBULIN, 2018-2032 (USD MILLION)
TABLE 161. NORTH AMERICA PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY IMMUNOGLOBULIN, 2018-2032 (USD MILLION)
TABLE 162. NORTH AMERICA PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
TABLE 163. NORTH AMERICA PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 164. NORTH AMERICA PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
TABLE 165. NORTH AMERICA PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY TREATMENT PATTERN, 2018-2032 (USD MILLION)
TABLE 166. NORTH AMERICA PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY PLASMA SOURCE TYPE, 2018-2032 (USD MILLION)
TABLE 167. NORTH AMERICA PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY LINE OF THERAPY, 2018-2032 (USD MILLION)
TABLE 168. NORTH AMERICA PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY THERAPY COMBINATION, 2018-2032 (USD MILLION)
TABLE 169. NORTH AMERICA PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
TABLE 170. NORTH AMERICA PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 171. LATIN AMERICA PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 172. LATIN AMERICA PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
TABLE 173. LATIN AMERICA PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY ALBUMIN, 2018-2032 (USD MILLION)
TABLE 174. LATIN AMERICA PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY COAGULATION FACTOR, 2018-2032 (USD MILLION)
TABLE 175. LATIN AMERICA PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY HYPERIMMUNE GLOBULIN, 2018-2032 (USD MILLION)
TABLE 176. LATIN AMERICA PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY IMMUNOGLOBULIN, 2018-2032 (USD MILLION)
TABLE 177. LATIN AMERICA PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
TABLE 178. LATIN AMERICA PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 179. LATIN AMERICA PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
TABLE 180. LATIN AMERICA PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY TREATMENT PATTERN, 2018-2032 (USD MILLION)
TABLE 181. LATIN AMERICA PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY PLASMA SOURCE TYPE, 2018-2032 (USD MILLION)
TABLE 182. LATIN AMERICA PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY LINE OF THERAPY, 2018-2032 (USD MILLION)
TABLE 183. LATIN AMERICA PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY THERAPY COMBINATION, 2018-2032 (USD MILLION)
TABLE 184. LATIN AMERICA PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
TABLE 185. LATIN AMERICA PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 186. EUROPE PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 187. EUROPE PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
TABLE 188. EUROPE PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY ALBUMIN, 2018-2032 (USD MILLION)
TABLE 189. EUROPE PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY COAGULATION FACTOR, 2018-2032 (USD MILLION)
TABLE 190. EUROPE PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY HYPERIMMUNE GLOBULIN, 2018-2032 (USD MILLION)
TABLE 191. EUROPE PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY IMMUNOGLOBULIN, 2018-2032 (USD MILLION)
TABLE 192. EUROPE PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
TABLE 193. EUROPE PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 194. EUROPE PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
TABLE 195. EUROPE PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY TREATMENT PATTERN, 2018-2032 (USD MILLION)
TABLE 196. EUROPE PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY PLASMA SOURCE TYPE, 2018-2032 (USD MILLION)
TABLE 197. EUROPE PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY LINE OF THERAPY, 2018-2032 (USD MILLION)
TABLE 198. EUROPE PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY THERAPY COMBINATION, 2018-2032 (USD MILLION)
TABLE 199. EUROPE PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
TABLE 200. EUROPE PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 201. MIDDLE EAST PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 202. MIDDLE EAST PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
TABLE 203. MIDDLE EAST PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY ALBUMIN, 2018-2032 (USD MILLION)
TABLE 204. MIDDLE EAST PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY COAGULATION FACTOR, 2018-2032 (USD MILLION)
TABLE 205. MIDDLE EAST PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY HYPERIMMUNE GLOBULIN, 2018-2032 (USD MILLION)
TABLE 206. MIDDLE EAST PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY IMMUNOGLOBULIN, 2018-2032 (USD MILLION)
TABLE 207. MIDDLE EAST PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
TABLE 208. MIDDLE EAST PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 209. MIDDLE EAST PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
TABLE 210. MIDDLE EAST PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY TREATMENT PATTERN, 2018-2032 (USD MILLION)
TABLE 211. MIDDLE EAST PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY PLASMA SOURCE TYPE, 2018-2032 (USD MILLION)
TABLE 212. MIDDLE EAST PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY LINE OF THERAPY, 2018-2032 (USD MILLION)
TABLE 213. MIDDLE EAST PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY THERAPY COMBINATION, 2018-2032 (USD MILLION)
TABLE 214. MIDDLE EAST PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
TABLE 215. MIDDLE EAST PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 216. AFRICA PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 217. AFRICA PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
TABLE 218. AFRICA PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY ALBUMIN, 2018-2032 (USD MILLION)
TABLE 219. AFRICA PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY COAGULATION FACTOR, 2018-2032 (USD MILLION)
TABLE 220. AFRICA PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY HYPERIMMUNE GLOBULIN, 2018-2032 (USD MILLION)
TABLE 221. AFRICA PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY IMMUNOGLOBULIN, 2018-2032 (USD MILLION)
TABLE 222. AFRICA PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
TABLE 223. AFRICA PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 224. AFRICA PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
TABLE 225. AFRICA PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY TREATMENT PATTERN, 2018-2032 (USD MILLION)
TABLE 226. AFRICA PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY PLASMA SOURCE TYPE, 2018-2032 (USD MILLION)
TABLE 227. AFRICA PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY LINE OF THERAPY, 2018-2032 (USD MILLION)
TABLE 228. AFRICA PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY THERAPY COMBINATION, 2018-2032 (USD MILLION)
TABLE 229. AFRICA PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
TABLE 230. AFRICA PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 231. ASEAN PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 232. ASEAN PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
TABLE 233. ASEAN PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY ALBUMIN, 2018-2032 (USD MILLION)
TABLE 234. ASEAN PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY COAGULATION FACTOR, 2018-2032 (USD MILLION)
TABLE 235. ASEAN PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY HYPERIMMUNE GLOBULIN, 2018-2032 (USD MILLION)
TABLE 236. ASEAN PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY IMMUNOGLOBULIN, 2018-2032 (USD MILLION)
TABLE 237. ASEAN PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
TABLE 238. ASEAN PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 239. ASEAN PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
TABLE 240. ASEAN PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY TREATMENT PATTERN, 2018-2032 (USD MILLION)
TABLE 241. ASEAN PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY PLASMA SOURCE TYPE, 2018-2032 (USD MILLION)
TABLE 242. ASEAN PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY LINE OF THERAPY, 2018-2032 (USD MILLION)
TABLE 243. ASEAN PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY THERAPY COMBINATION, 2018-2032 (USD MILLION)
TABLE 244. ASEAN PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
TABLE 245. ASEAN PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 246. GCC PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 247. GCC PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
TABLE 248. GCC PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY ALBUMIN, 2018-2032 (USD MILLION)
TABLE 249. GCC PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY COAGULATION FACTOR, 2018-2032 (USD MILLION)
TABLE 250. GCC PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY HYPERIMMUNE GLOBULIN, 2018-2032 (USD MILLION)
TABLE 251. GCC PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY IMMUNOGLOBULIN, 2018-2032 (USD MILLION)
TABLE 252. GCC PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
TABLE 253. GCC PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 254. GCC PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
TABLE 255. GCC PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY TREATMENT PATTERN, 2018-2032 (USD MILLION)
TABLE 256. GCC PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY PLASMA SOURCE TYPE, 2018-2032 (USD MILLION)
TABLE 257. GCC PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY LINE OF THERAPY, 2018-2032 (USD MILLION)
TABLE 258. GCC PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY THERAPY COMBINATION, 2018-2032 (USD MILLION)
TABLE 259. GCC PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
TABLE 260. GCC PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 261. EUROPEAN UNION PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 262. EUROPEAN UNION PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
TABLE 263. EUROPEAN UNION PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY ALBUMIN, 2018-2032 (USD MILLION)
TABLE 264. EUROPEAN UNION PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY COAGULATION FACTOR, 2018-2032 (USD MILLION)
TABLE 265. EUROPEAN UNION PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY HYPERIMMUNE GLOBULIN, 2018-2032 (USD MILLION)
TABLE 266. EUROPEAN UNION PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY IMMUNOGLOBULIN, 2018-2032 (USD MILLION)
TABLE 267. EUROPEAN UNION PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
TABLE 268. EUROPEAN UNION PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 269. EUROPEAN UNION PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
TABLE 270. EUROPEAN UNION PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY TREATMENT PATTERN, 2018-2032 (USD MILLION)
TABLE 271. EUROPEAN UNION PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY PLASMA SOURCE TYPE, 2018-2032 (USD MILLION)
TABLE 272. EUROPEAN UNION PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY LINE OF THERAPY, 2018-2032 (USD MILLION)
TABLE 273. EUROPEAN UNION PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY THERAPY COMBINATION, 2018-2032 (USD MILLION)
TABLE 274. EUROPEAN UNION PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
TABLE 275. EUROPEAN UNION PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 276. BRICS PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 277. BRICS PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
TABLE 278. BRICS PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY ALBUMIN, 2018-2032 (USD MILLION)
TABLE 279. BRICS PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY COAGULATION FACTOR, 2018-2032 (USD MILLION)
TABLE 280. BRICS PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY HYPERIMMUNE GLOBULIN, 2018-2032 (USD MILLION)
TABLE 281. BRICS PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY IMMUNOGLOBULIN, 2018-2032 (USD MILLION)
TABLE 282. BRICS PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
TABLE 283. BRICS PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 284. BRICS PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
TABLE 285. BRICS PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY TREATMENT PATTERN, 2018-2032 (USD MILLION)
TABLE 286. BRICS PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY PLASMA SOURCE TYPE, 2018-2032 (USD MILLION)
TABLE 287. BRICS PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY LINE OF THERAPY, 2018-2032 (USD MILLION)
TABLE 288. BRICS PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY THERAPY COMBINATION, 2018-2032 (USD MILLION)
TABLE 289. BRICS PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
TABLE 290. BRICS PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 291. G7 PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 292. G7 PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
TABLE 293. G7 PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY ALBUMIN, 2018-2032 (USD MILLION)
TABLE 294. G7 PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY COAGULATION FACTOR, 2018-2032 (USD MILLION)
TABLE 295. G7 PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY HYPERIMMUNE GLOBULIN, 2018-2032 (USD MILLION)
TABLE 296. G7 PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY IMMUNOGLOBULIN, 2018-2032 (USD MILLION)
TABLE 297. G7 PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
TABLE 298. G7 PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 299. G7 PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
TABLE 300. G7 PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY TREATMENT PATTERN, 2018-2032 (USD MILLION)
TABLE 301. G7 PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY PLASMA SOURCE TYPE, 2018-2032 (USD MILLION)
TABLE 302. G7 PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY LINE OF THERAPY, 2018-2032 (USD MILLION)
TABLE 303. G7 PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY THERAPY COMBINATION, 2018-2032 (USD MILLION)
TABLE 304. G7 PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
TABLE 305. G7 PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 306. NATO PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 307. NATO PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
TABLE 308. NATO PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY ALBUMIN, 2018-2032 (USD MILLION)
TABLE 309. NATO PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY COAGULATION FACTOR, 2018-2032 (USD MILLION)
TABLE 310. NATO PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY HYPERIMMUNE GLOBULIN, 2018-2032 (USD MILLION)
TABLE 311. NATO PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY IMMUNOGLOBULIN, 2018-2032 (USD MILLION)
TABLE 312. NATO PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
TABLE 313. NATO PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 314. NATO PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
TABLE 315. NATO PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY TREATMENT PATTERN, 2018-2032 (USD MILLION)
TABLE 316. NATO PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY PLASMA SOURCE TYPE, 2018-2032 (USD MILLION)
TABLE 317. NATO PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY LINE OF THERAPY, 2018-2032 (USD MILLION)
TABLE 318. NATO PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY THERAPY COMBINATION, 2018-2032 (USD MILLION)
TABLE 319. NATO PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
TABLE 320. NATO PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 321. UNITED STATES PLASMA PROTEIN THERAPEUTICS MARKET SIZE, 2018-2032 (USD MILLION)
TABLE 322. UNITED STATES PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
TABLE 323. UNITED STATES PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY ALBUMIN, 2018-2032 (USD MILLION)
TABLE 324. UNITED STATES PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY COAGULATION FACTOR, 2018-2032 (USD MILLION)
TABLE 325. UNITED STATES PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY HYPERIMMUNE GLOBULIN, 2018-2032 (USD MILLION)
TABLE 326. UNITED STATES PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY IMMUNOGLOBULIN, 2018-2032 (USD MILLION)
TABLE 327. UNITED STATES PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
TABLE 328. UNITED STATES PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 329. UNITED STATES PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
TABLE 330. UNITED STATES PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY TREATMENT PATTERN, 2018-2032 (USD MILLION)
TABLE 331. UNITED STATES PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY PLASMA SOURCE TYPE, 2018-2032 (USD MILLION)
TABLE 332. UNITED STATES PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY LINE OF THERAPY, 2018-2032 (USD MILLION)
TABLE 333. UNITED STATES PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY THERAPY COMBINATION, 2018-2032 (USD MILLION)
TABLE 334. UNITED STATES PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
TABLE 335. UNITED STATES PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 336. CANADA PLASMA PROTEIN THERAPEUTICS MARKET SIZE, 2018-2032 (USD MILLION)
TABLE 337. CANADA PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
TABLE 338. CANADA PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY ALBUMIN, 2018-2032 (USD MILLION)
TABLE 339. CANADA PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY COAGULATION FACTOR, 2018-2032 (USD MILLION)
TABLE 340. CANADA PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY HYPERIMMUNE GLOBULIN, 2018-2032 (USD MILLION)
TABLE 341. CANADA PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY IMMUNOGLOBULIN, 2018-2032 (USD MILLION)
TABLE 342. CANADA PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
TABLE 343. CANADA PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 344. CANADA PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
TABLE 345. CANADA PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY TREATMENT PATTERN, 2018-2032 (USD MILLION)
TABLE 346. CANADA PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY PLASMA SOURCE TYPE, 2018-2032 (USD MILLION)
TABLE 347. CANADA PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY

Companies Mentioned

The companies featured in this Plasma Protein Therapeutics market report include:
  • Abeona Therapeutics Inc.
  • ADMA Biologics, Inc.
  • Amgen Inc.
  • Baxter International Inc.
  • Bayer AG
  • Bharat Serums and Vaccines Limited
  • Bio Products Laboratory Limited
  • Biogen Inc.
  • BioMarin Pharmaceutical Inc.
  • Biotest AG
  • China Biologic Products Holdings, Inc.
  • CSL Limited
  • Emergent BioSolutions Inc.
  • F. Hoffmann-La Roche Ltd.
  • GC Biopharma Corp.
  • Grifols S.A.
  • Hualan Biological Engineering, Inc.
  • Intas Pharmaceuticals Limited
  • Kamada Ltd.
  • Kedrion S.p.A.
  • LFB S.A.
  • Novo Nordisk A/S
  • Octapharma AG
  • Pfizer Inc.
  • Prothya Biosolutions B.V.
  • Sanofi S.A.
  • Sanquin Plasma Products B.V.
  • Shanghai RAAS Blood Products Co., Ltd.
  • Shenzhen Kangtai Biological Products Co., Ltd.
  • Takeda Pharmaceutical Company Limited

Table Information

Report AttributeDetails
No. of Pages195
PublishedJune 2026
Forecast Period2026 - 2032
Estimated Market Value ( USD ) in 2026 $ 31.97 Billion
Forecasted Market Value ( USD ) by 2032 $ 43.78 Billion
Compound Annual Growth Rate5.3%
Regions CoveredGlobal
No. of Companies Mentioned31

Related Topics

Related Reports

Plasma Protein Therapeutics - Global Strategic Business Report - Product Image

Plasma Protein Therapeutics - Global Strategic Business Report

  • Report
  • 183 Pages
  • Global
From
Plasma Protein Therapeutics Market Report 2026 - Product Image

Plasma Protein Therapeutics Market Report 2026

  • Report
  • 250 Pages
  • Global
From
Plasma Protein Therapeutics Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2021-2031 - Product Image

Plasma Protein Therapeutics Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2021-2031

  • Report
  • 181 Pages
  • Global
From
Plasma Protein Therapeutics Market Outlook 2025-2034: Market Share, and Growth Analysis - Product Image

Plasma Protein Therapeutics Market Outlook 2025-2034: Market Share, and Growth Analysis

  • Report
  • 160 Pages
  • Global
From
Plasma Protein Therapeutics Market Report and Forecast 2025-2034 - Product Image

Plasma Protein Therapeutics Market Report and Forecast 2025-2034

  • Report
  • 350 Pages
  • Global
From

About the Plasma Protein Drug Market

The Plasma Protein Drug market is a subset of the biopharmaceutical industry, focusing on the development and production of drugs derived from human plasma proteins. These drugs are used to treat a variety of conditions, including immune deficiencies, bleeding disorders, and other rare diseases. Plasma protein drugs are typically produced through fractionation, a process that separates the proteins from the plasma. This process is used to create a variety of products, including albumin, immunoglobulins, and clotting factors. The Plasma Protein Drug market is highly regulated, with stringent safety and quality standards in place to ensure the safety of the products. Additionally, the market is highly competitive, with a number of companies vying for market share. Some of the major players in the Plasma Protein Drug market include CSL Behring, Grifols, Octapharma, Kedrion, and Biotest. Show Less Read more

Copyright © 2002-2026 Research and Markets. All Rights Reserved.